Gaithersburg, MD, October 20, 2015 – MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, announces the appointment of Spinco Biotech Pvt Ltd. as the exclusive authorized distributor of the MaxCyte STX® Scalable Transfection System and the MaxCyte VLX® Large Scale Transfection System in India.
“With the growing biologic and drug discovery market in India, there has been a great deal of interest in the MaxCyte platform,” stated Karen Donato, Ph.D., Executive Vice President, Business Development & Marketing at MaxCyte. “MaxCyte is pleased to be able to work with Spinco Biotech, the preferred provider of analytical and life science instrumentation for the scientific community in India. With a proven track record of more than 34 years of bringing life science instrumentation to researchers, Spinco Biotech will provide a vital link between MaxCyte and this market.
With more than 30 offices, Spinco Biotech distributes instruments and consumables for some the biggest manufacturers in the biotechnology market. Contact information for Spinco Biotech can be found on the MaxCyte website.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, for rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information visit /